Skip to main content
  • Home
  • Malaysia In Focus - Reverse Cardiac Remodelling Educational Programme

Malaysia In Focus - Reverse Cardiac Remodelling Educational Programme

Topic:
  • Heart Failure

Available Credit:

  • 1.00 MMA

Course Published On:

Course Expiry Date:

Overview

This on-demand programme, Malaysia In Focus - Reverse Cardiac Remodelling Educational Programme, has been developed to further education among practicing cardiologists to ensure understanding of the latest developments in reverse cardiac remodelling in heart failure, how emerging data relates to current practice in Malaysia, and is intended to support the application of current understanding of treatment strategies for heart failure, and the role of cardiac remodelling, biomarkers, and provide a review of trials and latest data..

 

The programme brings together a leading international faculty from Malaysian, US, UK, and Italy, for a seven-part series.

Endorsement

This programme is endorsed by the National Heart Association to promote quality cardiovascular care through education.

Support

This programme is supported by an unrestricted educational grant from Novartis. Novartis had no involvement in the organisation of the programme.

Disclosure

In compliance with Malaysian Medical Association (MMA) guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.

 

The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CPD activities.

 

This programme is supported by an unrestricted educational grant from Novartis. The scientific programme has not been influenced in any way by the sponsor.

Faculty Disclosures

Dato’ Dr David Chew 

  • No conflicts of interest to declare pertaining to this programme.

 

Dr James Januzzi 

  • Grant support from Novartis Pharmaceuticals, Applied Therapeutics, and Innolife
  • Consulting income from Abbott Diagnostics, Janssen, Novartis, Quidel and Roche Diagnostics
  • Clinical endpoint committees/data safety monitoring boards for Abbott, AbbVie, Amgen, CVRx, Janssen, MyoKardia, and Takeda
  • Trustee, American College of Cardiology

 

Dr Akshay Desai

  • Received consulting fees from Abbott, Alnylam, AstraZeneca, Biofourmis, Boston Scientific, Boehringer-Ingelheim, DalCor Pharma,  Merck, Novartis, Relypsa, Regeneron and Research Grants from AstraZeneca, Alnylam, and Novartis

 

Prof Andrew Coats

  • No conflicts of interest to declare pertaining to this programme.

 

Dr Michele Senni

  • Financial interest for consultancy with: Novartis, Merck, Bayer, Vifor Pharma, Abbott, Boehringer Ingelheim, Astra-Zeneca, Bioventrix, Servier

 

Dr Pardeep Jhund

  • No conflicts of interest to declare pertaining to this programme.

Terms & Conditions

Radcliffe Education requires contributors to our CME/CPD programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.

 

This programme ‘Malaysia In Focus - ARNI Data And Its Implications On Clinical Practice’ is accredited by the Malaysian Medical Association (MMA)  for 1 hour of external CPD credits.

 

Each participant should claim only those hours of credit that have actually been spent in the educational activity.

Instructions to Participants

There is no fee for taking part in this online learning activity.

 

Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.

 

To complete the course and claim certification participants must:

  • Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.
  • Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.

Target Audience

  • Cardiologists, heart failure specialists, allied health professionals, and GPs with a specialist interest in heart failure.

Learning Objectives

  • Define cardiac remodelling, with particular focus on the influence of cardiovascular damage, pathogenic risk factors and the structural and functional changes in the left ventricle.
  • List the main clinical implications of cardiac remodelling.
  • Summarise the relationship between circulating biomarkers, such as NT-proBNP, troponin and sST2, with the extent left ventricular remodelling in subjects with HF.
  • Interpret the most recent clinical data from pharmacological and device-based studies in HFrEF and HfpEF.
  • Recall the evidence for reverse cardiac remodelling brought about through ARNi therapy, including (but not limited to) PROVE-HF and EVALUATE-HF.
  • Review real-world insight into the impact that ARNi therapy has on cardiac reverse remodelling.
Register now Log in

Speaker

David Chew

Dato' Dr David Chew Soon Ping is a Consultant Cardiologist at Cardiac Vascular Sentral  Kuala Lumpur (CVSKL) in Malaysia.

View full profile

James Januzzi

Massachusetts General Hospital

Dr James L Januzzi,  is an Associate Professor of Medicine at Harvard Medical School and Director of the Cardiac Intensive Care Unit at Massachusetts General Hospital. He has an in-depht experience as a teacher and leads a research programme with specific focus on cardiac biomarker testing.

View full profile

Akshay Desai

Brigham and Women’s Hospital, Boston, MA, US

Prof Akshay Desai is a cardiovascular medicine specialist and the director of the Cardiomyopathy and Heart Failure Program at Brigham and Women’s Hospital. Dr Desai’s research focuses on improving care and outcomes for HF patients, as well as strategies to reduce heart failure readmissions. 

View full profile

Andrew Coats

Monash University, AU and University of Warwick, UK

Prof Coats is Joint Academic Vice-President of Monash University, Australia and the University of Warwick, UK. His research greatly influenced the treatment for chronic heart failure, promoting exercise training instead of bed rest. He has a vast experience in education and publishing.

View full profile

Michele Senni

Dr Michele Senni served from 2004 to 2013 as Head of General Medicine 2 Cardiovascular Hospital of Bergamo. From 2009 to 2010 he was Chairman of the National Association of Cardiologists and Hospital Doctors (ANMCO). Today he is Director of Cardiology 1.

View full profile

Pardeep Jhund

Dr Pardeep Jhund is a Reader in Cardiology at the University of Glasgow, UK.

View full profile

This programme accredited by the Malaysian Medical Association (MMA) for 1 external CPD credit. Once the course is completed, there are instructions on how to receive your credit.

 

AVAILABLE CREDIT

1.00 Malaysian Medical Association (MMA)

Related Courses

SGLT-2 Inhibitors - Another Piece of the Puzzle in Heart Failure
  • 1 EBAC

Learning objectives

  • Recall the results of key trials in HFmrEF in different patients' sub-groups
  • Describe how SGLT-2 inhibitors can be used across the range of LVEF
  • Apply emerging diagnostic approaches for HFpEF and HFmrEF
  • Implement best-practice strategies across the range of LVEF
See more
Making Gains in HFpEF: An Appraisal of Where We Are Now

Learning objectives

  • Identify HFpEF patients who may benefit from being initiated on an SGLT-2 inhibitor
  • Recall current inertia rates amongst prescribers who manage heart failure
  • Adopt effective treatment strategies for HFpEF patients early in the disease course
  • Recall current guideline directed medical therapy options in HFpEF
  • Review clinical, real world and quality of life evidence for the use of SGLT-2 inhibitors in HFpEF
See more
Heart Failure Management in a Changing Paradigm
  • 1 EBAC

Learning objectives

  • Recall the utility of EF in heart failure treatment, patient selection and treatment response
  • Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy
  • InIncorporate quality of life measures for assessing therapeutic efficacy in HF
  • Recall outcomes from heart failure trials from recent congress and publications and their impact on practice
See more
The 2022 ACC Heart Failure Guidelines: What Do They Mean for Your Practice?

Learning objectives

  • Summarise the main updates to the 2022 ACC heart failure (HF) guidelines
  • Compare updates from the ACC with the 2021 ESC HF guidelines
  • Recall guideline recommendations for the initiation of foundational therapy for heart failure
  • Adopt foundational GMDT early in the disease course
  • Postulate how ejection fraction will be used in future trials and in future guidelines
  • Review existing and forthcoming trial evidence on SGLT-2 inhibitors in HFpEF
See more
HFO 2022 - Session 3.3: Live Case & Discussion
  • 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

Learning objectives

  • Select foundational and advanced management strategies in complex patients
  • Discuss the validity of using ejection fraction to determine optimal treatment strategies
  • Assess the likely impact of health technology on future practice
  • Identify the underlying causes of heart failure
  • Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
  • Assess the impact of the multidisciplinary team on heart failure outcomes
  • Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
See more
HFO 2022 - Session 3.1 & 3.2: Quality of Life and Multi-disciplinary Care in HF
  • 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

Learning objectives

  • Select foundational and advanced management strategies in complex patients
  • Discuss the validity of using ejection fraction to determine optimal treatment strategies
  • Assess the likely impact of health technology on future practice
  • Identify the underlying causes of heart failure
  • Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
  • Assess the impact of the multidisciplinary team on heart failure outcomes
  • Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
See more
HFO 2022 - Session 2.5 Practical Theory & Hot Topics: Advanced HF Care
  • 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

Learning objectives

  • Select foundational and advanced management strategies in complex patients
  • Discuss the validity of using ejection fraction to determine optimal treatment strategies
  • Assess the likely impact of health technology on future practice
  • Identify the underlying causes of heart failure
  • Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
  • Assess the impact of the multidisciplinary team on heart failure outcomes
  • Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
See more
HFO 2022 - Session 2.3 Practical Theory & Hot Topics: HF Aetiology
  • 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

Learning objectives

  • Select foundational and advanced management strategies in complex patients
  • Discuss the validity of using ejection fraction to determine optimal treatment strategies
  • Assess the likely impact of health technology on future practice
  • Identify the underlying causes of heart failure
  • Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
  • Assess the impact of the multidisciplinary team on heart failure outcomes
  • Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
See more
HFO 2022 - Session 2.2 Live Case and Discussion
  • 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

Learning objectives

  • Select foundational and advanced management strategies in complex patients
  • Discuss the validity of using ejection fraction to determine optimal treatment strategies
  • Assess the likely impact of health technology on future practice
  • Identify the underlying causes of heart failure
  • Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
  • Assess the impact of the multidisciplinary team on heart failure outcomes
  • Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
See more
HFO 2022 - Session 1.4 Practical Theory & Hot Topics: Transitioning Care and Monitoring Technology
  • 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

Learning objectives

  • Select foundational and advanced management strategies in complex patients
  • Discuss the validity of using ejection fraction to determine optimal treatment strategies
  • Assess the likely impact of health technology on future practice
  • Identify the underlying causes of heart failure
  • Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
  • Assess the impact of the multidisciplinary team on heart failure outcomes
  • Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
See more